- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Advancing Care in Pediatric Plaque Psoriasis: Emerging Treatments and Management Strategies : Episode 7
Opinion
Video
Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis
Author(s):
Key Takeaways
- Roflumilast is used for COPD, reducing exacerbations but may cause gastrointestinal side effects.
- Apremilast is indicated for psoriatic arthritis and plaque psoriasis, with a favorable safety profile.
Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.
Video Player is loading.
Video content above is prompted by the following:
- Currently there are two approved PDE4 inhibitors in this category. Could you provide an overview of these systemic treatments, highlighting their key differences and considerations in terms of efficacy and safety?
Related Videos
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Differentiating Between JAK Inhibitors in Clinical Practice
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Laboratory Monitoring with Oral JAK Inhibitors
Related Content
